Cancer

Lilly taps Abbisko for $1.9B discovery deal

Thu, 25 Jun 2026 09:00:00 -0400

Abbisko Therapeutics Co. Ltd. has entered a research collaboration and license agreement with Eli Lilly and Co. to discover and develop innovative medicines across multiple targets, with the aim of advancing novel drug candidates with global potential.

University of Melbourne patent divulges new radionuclide-drug conjugates

Thu, 25 Jun 2026 09:00:00 -0400

The University of Melbourne has reported new radionuclide-drug conjugates (RDCs) comprising copper ion chelated to sarcophagine covalently bound to a peptide-targeting glutamate carboxypeptidase 2 (FOLH1; NAALAD1; PSMA) and another peptide targeting gastrin-releasing peptide receptor (GRPR).

University North Carolina patents new SLC7A5 inhibitors

Thu, 25 Jun 2026 09:00:00 -0400

The University of North Carolina at Chapel Hill has disclosed new large neutral amino acids transporter small subunit 1 (SLC7A5; LAT1) inhibitors reported to be useful for the diagnosis and treatment of cancer.

Combotope and Boehringer Ingelheim partner in cancer

Thu, 25 Jun 2026 09:00:00 -0400

Combotope Therapeutics ApS has established a strategic research collaboration with Boehringer Ingelheim Pharma GmbH & Co. KG that will leverage Combotope’s proprietary SMART-Phage platform to generate highly tumor-selective antibodies for next-generation cancer therapies.

GT-02897 exerts efficacy in preclinical multiple myeloma

Thu, 25 Jun 2026 09:00:00 -0400

Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential treatment of multiple myeloma.

Extracellular vesicle-based photoimmunotherapy for MDK+ solid tumors

Thu, 25 Jun 2026 09:00:00 -0400

Midkine (MDK) is a multifunctional heparin-binding cytokine highly overexpressed and extracellularly enriched in the tumor microenvironment (TME) of several cancers.

BMS’s dual CAR T-cell therapy shows efficacy in multiple myeloma

Thu, 25 Jun 2026 09:00:00 -0400

Researchers from Bristol Myers Squibb Co. (BMS) presented preclinical data on BMS-986453 (tunlucabtagene autoleucel), a dual-targeting BCMA×GPRC5D CAR T-cell therapy, in models of multiple myeloma.

Nuvectis shares continue to rally after $1.46B Haisco deal

Wed, 24 Jun 2026 12:00:00 -0400

Nuvectis Pharma Inc.’s shares climbed further after the oncology-focused biotech nabbed select rights to a late-stage complement factor B inhibitor (HSK-39297/NXP-100) and a phase I BRAF inhibitor (HSK-42360/NXP-200) from Haisco Pharmaceutical Group Co. Ltd. for $40 million up front.

Antares, Novartis pursuing undruggable cancer targets in $1.9B deal

Wed, 24 Jun 2026 12:00:00 -0400

Antares Therapeutics Inc. drew Novartis AG to the table for a potential $1.9 billion collaboration, including a $105 million up-front payment, to discover small-molecule programs against oncology targets considered to be undruggable. It’s Antares’ first partnership since spinning out of Scorpion Therapeutics Inc. about a year ago.

Lilly taps Abbisko for $1.9B discovery deal

Wed, 24 Jun 2026 12:00:00 -0400

J-Pharma drives first cancer LAT1 to phase III study with FDA nod

Tue, 23 Jun 2026 12:00:00 -0400

J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat (JPH‑203), in a global phase III Beacon-BTC study of biliary tract cancer following U.S. FDA alignment.

EFPIA report: Every €1 spent on new drugs returns €5.67 to Europe’s economy

Tue, 23 Jun 2026 12:00:00 -0400

The industry is stepping up its campaign to persuade European governments to increase their drugs budgets, in what is described as a landmark report making the case that spending on patented drugs is not a cost to be contained, but an investment in health and the economy.

China approves first CAR T for solid tumors

Tue, 23 Jun 2026 12:00:00 -0400

China’s National Medical Products Administration approved Carsgen Therapeutics Holdings Ltd.’s NDA for satricabtagene autoleucel (satri-cel, CT-041), marking the first global approval of a CAR T therapy for solid tumors. The autologous Claudin18.2-targeted CAR T was approved for patients with Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy.

Pfizer ADC, from Seagen M&A, fails in phase III NSCLC trial

Tue, 23 Jun 2026 12:00:00 -0400

Missing statistical significance on the primary overall survival phase III endpoint with antibody-drug conjugate (ADC) sigvotatug vedotin compared with docetaxel in non-small-cell lung cancer (NSCLC), Pfizer Inc., which gained the candidate through its $43 billion buyout of Seagen Inc. in 2023, is forging ahead based on subgroup signals, phase I data and an ongoing phase III Keytruda combination effort currently underway.

K2 nabs two Antengene bispecific TCEs in $2B license, option deal

Tue, 23 Jun 2026 09:00:00 -0400

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan.

Rin Institute discovers new insoluble fibrin-targeting ADCs

Tue, 23 Jun 2026 09:00:00 -0400

Rin Institute Inc. has disclosed antibody-drug conjugates consisting of an antibody targeting insoluble fibrin conjugated to MMAE through a plasmin-cleavable linker reported to be useful for the treatment of cancer.

EVmiR-885-5p limits TNBC spread in preclinical models

Mon, 22 Jun 2026 09:00:00 -0400

Researchers at Theramir Ltd. presented preclinical proof-of-concept data for a new extracellular vesicle (EV) platform engineered to deliver miR-885-5p (EVmiR885-5p), targeting leukocyte-specific protein-1 (LCP-1)-mediated cytoskeletal remodeling in triple-negative breast cancer (TNBC) models.

CATA-001 yields promising results for light chain multiple myeloma

Mon, 22 Jun 2026 09:00:00 -0400

Light chain multiple myeloma (LCMM) is a cancer driven by malignant plasma cells that produce excessive pathogenic free light chains (FLCs) that may cause kidney dysfunction and form amyloid deposits in key organs, thus leading to poor outcomes. Ab Studio Inc.’s CATA-001 is a bispecific antibody targeting both CD38 and aggregated light chains (ALs) designed to deplete CD38+ plasma cells and clear both circulating and tissue-deposited pathogenic FLC aggregates for the treatment of LCMM and AL amyloidosis.

K2 nabs two Antengene bispecific TCEs in $2B license, option deal

Mon, 22 Jun 2026 09:00:00 -0400

Nankai University and Accendatech present new majusculamide D derivatives

Fri, 19 Jun 2026 09:00:00 -0400

Scientists from Nankai University Tianjin and Accendatech Technology Co. Ltd. have identified a majusculamide D derivative found to be useful for the treatment of cancer.

Chinese scientists identify new macrocyclic compounds as kinase inhibitors

Fri, 19 Jun 2026 09:00:00 -0400

Henan Normal University and Henan Zhiwei Biological Engineering Co. Ltd. have discovered macrocyclic compounds acting as neurotrophic tyrosine kinase receptors (TRK) and/or proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or hepatocyte growth factor receptor (HGFR; MET) and/or macrophage colony-stimulating factor 1 receptor (CSF1R; CD115; c-Fms) and/or ALK tyrosine kinase receptor inhibitors found to be potentially useful for the treatment of cancer and pain.

Hangzhou Innogate Pharma discovers new KAT inhibitors

Fri, 19 Jun 2026 09:00:00 -0400

Hangzhou Innogate Pharma Co. Ltd. has patented inhibitors of histone acetyltransferase KAT5 (Tip60) and/or KAT6A (MOZ; MYST-3) and/or KAT6B (MOZ2; MYST-4) and/or KAT7 (HBO-1; MYST-2) and/or KAT8 (hMOF; MYST-1) reported to be useful for the treatment of cancer.

Ellison Medical Institute signs license agreement for QED-203

Fri, 19 Jun 2026 09:00:00 -0400

Uniquest Pty Ltd., the commercialization company of the University of Queensland, has entered into an exclusive license agreement with the Ellison Medical Institute (EMI) to develop and commercialize the University of Queensland’s QED-203 for metastatic castration-resistant prostate cancer.

Evaxion shares data from characterization of EVX-04

Fri, 19 Jun 2026 09:00:00 -0400

Evaxion A/S has developed EVX-04, an AI-designed DNA vaccine encoding 1β endogenous retroviruses (ERVs)-derived antigenic fragments to induce broad antigen-specific T-cell responses targeting acute myeloid leukemia blasts expressing ERV antigens.

J-Pharma drives first cancer LAT1 to phase III study with FDA nod

Thu, 18 Jun 2026 12:00:00 -0400

Sunshine Lake Pharma identifies new GTPase KRAS G12C inhibitors

Thu, 18 Jun 2026 09:00:00 -0400

Sunshine Lake Pharma Co. Ltd. has patented GTPase KRAS (G12C mutant) inhibitors found to be potentially useful for the treatment of cancer.

Convalife presents new dual CDK4/cyclin D1 and CDK9 inhibitors

Thu, 18 Jun 2026 09:00:00 -0400

Researchers from Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have described dual CDK4/cyclin D1 and cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.

Sichuan Kelun-Biotech Biopharmaceutical patents new heterocyclic compounds

Thu, 18 Jun 2026 09:00:00 -0400

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed heterocyclic compounds and their antibody-drug conjugates reported to be useful for the treatment of cancer.

KANSL2 is oncogene and actionable biomarker in multiple myeloma

Thu, 18 Jun 2026 09:00:00 -0400

Due to the availability of drugs targeting histone acetylation and associated reader proteins, the equilibrium of histone acetylation and deacetylation has attracted attention in multiple myeloma as a potential therapeutic target. Therefore, the identification of novel predictive biomarkers for multiple myeloma patient selection for epigenetic therapies is urgently needed.

CC-3 antibody shows antitumoral activity in penile cancer

Thu, 18 Jun 2026 09:00:00 -0400

Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies achieve objective response rates of 40%-50%, while immunotherapy has not been established.